Results 121 to 130 of about 546 (157)
Some of the next articles are maybe not open access.
Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab
Journal of the American Pharmacists Association, 2014Antibacterial agents Skin and skin structure infections are most often caused by Grampositive bacteria such as streptococci and staphylococci. The number of these infections that are caused by methicillin-resistant Staphylococcus aureus (MRSA) has rapidly increased in recent years in both the community and hospital settings.
Daniel A, Hussar, Angelique, Nguyen
openaire +2 more sources
177Lutetium-Tedizolid for Imaging and Treatment of Infection
2022Enfeksiyon hastalıkları hala dünyada temel sağlık problemlerinden birini oluşturmaktadır. Enfeksiyonun erken aşamalarda teşhisi ve kanser veya inflamasyon gibi diğer patolojilerden ayrımı, enfeksiyonu akut aşamalarda tedavi etmede kritik rol oynamaktadır.
KARPUZ, Merve +3 more
openaire +2 more sources
The role of tedizolid in skin and soft tissue infections
Current Opinion in Infectious Diseases, 2018Purpose of review Tedizolid is a second-generation oxazolidinone with activity against Gram-positive bacteria, including MRSA isolates resistant to linezolid. Pivotal clinical trials showed that tedizolid at 200 mg once-daily for 6 days is not inferior to linezolid 600 mg twice daily for 10 days in patients with SSTI.
Emilio, Bouza +2 more
openaire +2 more sources
Tedizolid: a service evaluation in a large UK teaching hospital
European Journal of Clinical Microbiology & Infectious Diseases, 2020Tedizolid is a new oxazolidinone antibiotic with little real-life data on use outside of skin and soft tissue infections. There is a paucity of safety evidence in courses greater than 6 days. Our centre uses tedizolid predominantly when linezolid-associated adverse events have occurred. This service evaluation describes our experience to date.
Joshua A. York +7 more
openaire +2 more sources
Tedizolid for osteoarticular infections: Evaluation of the published evidence
European Journal of PharmacologyTedizolid phosphate, an oxazolidinone antibiotic, has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). However, its off-label use has been reported in various infections, including osteoarticular infections.A systematic review of data from PubMed, Scopus, and Web of Science was conducted to evaluate the ...
Veatriki Athanasiou +4 more
openaire +2 more sources
Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects
Clinical Pharmacology in Drug Development, 2018AbstractTedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infections in adults. We evaluated the pharmacokinetics of tedizolid in elderly subjects to guide dosing recommendations. In an open‐label phase 1 study (ClinicalTrials.gov identifier NCT01496677), 14 elderly (≥65 years) and 14 younger control (18–45 ...
Shawn D, Flanagan +2 more
openaire +2 more sources